Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017 (2017), Article ID 3732902, 6 pages
https://doi.org/10.1155/2017/3732902
Case Report

Waldenstrom’s Macroglobulinemia: A Report of Two Cases, One with Severe Retinopathy and One with Renal Failure

1Division of Hematology, Takasago-seibu Hospital, Takasago 676-0812, Japan
2Department of Internal Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
3The Center for Hematological Diseases, Takeda General Hospital, Kyoto 601-1495, Japan
4Division of Ophthalmology, Takasago-seibu Hospital, Takasago 676-0812, Japan
5Department of Urology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
6Department of Pathology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
7Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan

Correspondence should be addressed to Shinsaku Imashuku

Received 25 June 2017; Revised 16 September 2017; Accepted 3 October 2017; Published 31 October 2017

Academic Editor: Sergio Storti

Copyright © 2017 Naoko Kudo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Gertz, “Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management,” American Journal of Hematology, vol. 92, no. 2, pp. 209–217, 2017. View at Publisher · View at Google Scholar
  2. J. J. Castillo, R. Garcia-Sanz, E. Hatjiharissi et al., “Recommendations for the diagnosis and initial evaluation of patients with Waldenström macroglobulinaemia: a task force from the 8th International Workshop on Waldenström macroglobulinaemia,” British Journal of Haematology, vol. 175, no. 1, pp. 77–86, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. Lymphoma Study Group of Japanese Pathologists, “The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities,” Pathology International, vol. 50, no. 9, pp. 696–702, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. W. G. Morice, D. Chen, P. J. Kurtin, C. A. Hanson, and E. D. McPhail, “Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinemia,” Modern Pathology, vol. 22, no. 6, pp. 807–816, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Berger, A. Traverse-Glehen, P. Felman et al., “Clinicopathologic features of Waldenstrom’s macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?” Clinical Lymphoma, vol. 5, no. 4, pp. 220–224, 2005. View at Publisher · View at Google Scholar
  6. M. C. Kyrtsonis, G. Levidou, P. Korkolopoulou et al., “CD138 expression helps distinguishing Waldenström’s macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL),” Clinical Lymphoma Myeloma Leukemia, vol. 11, no. 1, pp. 99–102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. R. Hunter, G. Yang, L. Xu, X. Liu, J. J. Castillo, and S. P. Treon, “Genomics, signaling, and treatment of Waldenström macroglobulinemia,” Journal of Clinical Oncology, vol. 35, no. 9, pp. 994–1001, 2017. View at Publisher · View at Google Scholar
  8. V. Leblond, E. Kastritis, R. Advani et al., “Treatment recommendations from the Eighth International Workshop on Waldenström’s macroglobulinemia,” Blood, vol. 128, no. 10, pp. 1321–1328, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Alexander, D. Flanagan, K. Rege, A. Foss, and M. Hingorani, “Bilateral simultaneous central retinal vein occlusion secondary to hyperviscosity in Waldenstrom’s macroglobulinaemia,” Eye, vol. 22, no. 8, pp. 1089–1092, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Chanana, N. Gupta, and R. V. Azad, “Case report: bilateral simultaneous central retinal vein occlusion in Waldenström’s macroglobulinemia,” Optometry, vol. 80, no. 7, pp. 350–353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Vos, J. Gustine, H. G. Rennke et al., “Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes,” British Journal of Haematology, vol. 175, no. 4, pp. 623–630, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Castillo, A. J. Olszewski, S. Kanan, K. Meid, Z. R. Hunter, and S. P. Treon, “Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database,” British Journal of Haematology, vol. 169, no. 1, pp. 81–89, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Abeykoon, U. Yanamandra, and P. Kapoor, “New developments in the management of Waldenström macroglobulinemia,” Cancer Management Research, vol. 9, pp. 73–83, 2017. View at Publisher · View at Google Scholar
  14. M. N. Menke, G. T. Feke, J. W. McMeel, A. Branagan, Z. Hunter, and S. P. Treon, “Hyperviscosity-related retinopathy in Waldenstrom macroglobulinemia,” Archives of Ophthalmology, vol. 124, no. 11, pp. 1601–1606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Dimopoulos, E. Terpos, A. Chanan-Khan et al., “Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4976–4984, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. F. Pilon, P. S. Rhee, and L. V. Messner, “Bilateral, persistent serous macular detachments with Waldenström’s macroglobulinemia,” Optometry and Vision Science, vol. 82, no. 7, pp. 573–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Nishida, R. Hashida, M. Hatano, M. Hori, and K. Obara, “Optic nerve involvement of Waldenström’s macroglobulinemia: with autopsy findings,” Neurological Sciences, vol. 35, no. 8, pp. 1299–1302, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Merlini, L. Baldini, C. Broglia et al., “Prognostic factors in symptomatic Waldenström’s macroglobulinemia,” Seminars in Oncology, vol. 30, no. 2, pp. 211–215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. N. Menke, G. T. Feke, J. W. McMeel, and S. P. Treon, “Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom’s macroglobulinemia,” Investigative Ophthalmology & Visual Science, vol. 49, no. 3, pp. 1157–1160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Audard, B. Georges, P. Vanhille et al., “Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum,” Clinical Journal of American Society of Nephrology, vol. 3, no. 5, pp. 1339–1349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Chauvet, F. Bridoux, L. Ecotière et al., “Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients,” American Journal of Kidney Diseases, vol. 66, no. 5, pp. 756–767, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Kyle, S. P. Treon, R. Alexanian et al., “Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia,” Seminars in Oncology, vol. 30, no. 2, pp. 116–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Dimopoulos, E. Kastritis, M. Roussou et al., “Rituximab-based treatments in Waldenström’s macroglobulinemia,” Clinical Lymphoma and Myeloma, vol. 9, no. 1, pp. 59–61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Laszlo, G. Andreola, L. Rigacci et al., “Rituximab and subcutaneous 2-chloro-2-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2233–2238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Varettoni, E. Marchioni, M. Bonfichi et al., “Successful treatment with rituximab and bendamustine in a patient with newly diagnosed Waldenström’s macroglobulinemia complicated by Bing-Neel syndrome,” American Journal of Hematology, vol. 90, no. 8, pp. E152–E153, 2015. View at Publisher · View at Google Scholar · View at Scopus